CSF3 and acute myeloid leukemia: A study of TP53mut AML patients demonstrated that the combination of DEC, chidamide, a histone deacetylase inhibitor (HDACi) with a priming regimen consisting of omacetaxine mepesuccinate (an alkaloid herbal derivative), cytarabine, and G-CSF (HAG) yielded potent responses with an ORR of 71.4% and manageable toxicity [50].